Novo Nordisk

Thumbnail for Novo Nordisk to acquire three fill-finish facilities from Novo Holdings as part of Catalent merger

5 February 2024

Novo Nordisk to acquire three fill-finish facilities from Novo Holdings as part of Catalent merger

Thumbnail for Novo Nordisk partners with Omega Therapeutics and Cellarity

9 January 2024

Novo Nordisk partners with Omega Therapeutics and Cellarity

Thumbnail for Novo Nordisk completes COMBINE 3 phase 3a trial on Type 2 Diabetes

9 January 2024

Novo Nordisk completes COMBINE 3 phase 3a trial on Type 2 Diabetes

Thumbnail for Novo Nordisk Foundation launches US$260 million global initiative for respiratory vaccines

19 December 2023

Novo Nordisk Foundation launches US$260 million global initiative for respiratory vaccines

Thumbnail for UNHCR Kenya, Novo Nordisk Foundation, Grundfos Foundation unite to empower vulnerable communities

13 December 2023

UNHCR Kenya, Novo Nordisk Foundation, Grundfos Foundation unite to empower vulnerable communities

Thumbnail for Novo Nordisk sues Wells Pharmacy Network over semaglutide compounded drugs

1 December 2023

Novo Nordisk sues Wells Pharmacy Network over semaglutide compounded drugs

Thumbnail for Novo Nordisk explores flexible pricing options for weight-loss drug Wegovy

30 November 2023

Novo Nordisk explores flexible pricing options for weight-loss drug Wegovy

Thumbnail for Novo Nordisk invests US$2.3 billion in French facility to meet high demand for weight-loss and diabetes drugs

26 November 2023

Novo Nordisk invests US$2.3 billion in French facility to meet high demand for weight-loss and diabetes drugs

Thumbnail for Pharmaceutical giants capitalize on soaring obesity rates with revolutionary weight-loss drugs

20 November 2023

Pharmaceutical giants capitalize on soaring obesity rates with revolutionary weight-loss drugs

Thumbnail for Pharma giants Eli Lilly and Novo Nordisk drive retail investor interest amid weight-loss drug success

19 November 2023

Pharma giants Eli Lilly and Novo Nordisk drive retail investor interest amid weight-loss drug success